Affimed NV (LTS:0HL9)
$ 2.22 0.1082 (4.73%) Market Cap: 38.03 Mil Enterprise Value: 25.31 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 26/100

Q1 2024 Affimed NV Earnings Call Transcript

Jun 12, 2024 / 12:30PM GMT
Release Date Price: $7.23 (+11.40%)
Operator

Good day, everyone, and welcome to Affimed's first quarter 2024 earnings and corporate update call. (Operator instructions) As reminder, today's conference call is being recorded.

I would now like to introduce your host for today's call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed NV - Investor Relations

Thank you, Michelle, and thank you all for joining us today for our first quarter 2024 Update Call. Before we begin, I'd like to remind everyone that we issued the relevant press release and presentation on our website today, which you can find under the in the Investor Relations section on the call today, we have members of our management team, including Andreas Harstrick, our Chief Medical Officer and acting Chief Executive Officer; Wolfgang Fischer, our Chief Operating Officer; Denise Mueller, our Chief Business Officer; and Harry Welten, our Consulting Chief Financial Officer. Our financials today will be presented by our Vice President of Finance, Michael Wolf. The team will be available for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot